Want to see IN:AUROPHARMA full AI Analyst Report?
AUROPHARMA Stock Chart & Stats
₹1531.50
₹17.40(1.14%)
At close: 4:00 PM EDT
₹1531.50
₹17.40(1.14%)
Day’s Range― - ―
52-Week Range₹1,017.00 - ₹1,671.30
Previous CloseN/A
Volume850.22K
Average Volume (3M)40.80K
Market Cap
₹955.70B
Enterprise Value₹731.37K
Total Cash (Recent Filing)₹106.18B
Total Debt (Recent Filing)₹80.73B
Price to Earnings (P/E)25.8
Beta0.66
Next Earnings
Nov 09, 2026EPS Estimate
19.11Next Dividend Ex-DateN/A
Dividend Yield0.24%
Share Statistics
EPS (TTM)60.34
Shares Outstanding575,377,870
10 Day Avg. Volume31,329
30 Day Avg. Volume40,801
Financial Highlights & Ratios
PEG Ratio24.40
Price to Book (P/B)2.00
Price to Sales (P/S)2.25
P/FCF Ratio26.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)78.33
Revenue Forecast (FY)₹397.55B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageSustained low leverage gives Aurobindo durable financial flexibility: it can fund regulatory remediation, capacity investments, or short-term working capital without relying heavily on market funding. This buffer supports long-term operations in cyclical generics markets.
Improved Cash Generation And Positive Free Cash FlowA strong 2026 cash conversion and sharply higher free cash flow materially improves internal funding for capex, debt reduction, and product launches. While historical volatility exists, sustained FCF supports strategic investment and reduces reliance on external capital.
Vertically Integrated Generics And API ManufacturingIntegration across APIs and finished dosages supports cost control, supply security and margin resilience versus pure-play formulators. Diversified product forms (oral solids, injectables) and geography exposure reduce single-market dependence and strengthen competitive positioning.
Bears Say
Material Margin CompressionA drop from mid-50% to ~39% gross margin signals persistent pricing pressure or higher input costs that can structurally depress profitability. Lower gross margins reduce operating leverage, constrain reinvestment capacity and make earnings more sensitive to volume swings.
Moderate And Declining Returns On EquityA declining ROE near 9% indicates weakening capital efficiency and modest long-term shareholder returns. If sustained, this limits the firm's ability to attract investment and indicates challenges in translating revenue growth into proportionate profit growth.
History Of Uneven Free Cash Flow / Cash Conversion VolatilityPrior negative FCF years despite a strong 2026 rebound show cash conversion is cyclical and sensitive to capex and working capital. This volatility can hinder consistent dividends, limit predictable reinvestment, and raise refinancing risk in weaker cycles.
Aurobindo Pharma Ltd News
AUROPHARMA FAQ
What was Aurobindo Pharma Ltd’s price range in the past 12 months?
Aurobindo Pharma Ltd lowest stock price was ₹1017.00 and its highest was ₹1671.30 in the past 12 months.
What is Aurobindo Pharma Ltd’s market cap?
Aurobindo Pharma Ltd’s market cap is ₹955.70B.
When is Aurobindo Pharma Ltd’s upcoming earnings report date?
Aurobindo Pharma Ltd’s upcoming earnings report date is Nov 09, 2026 which is in 90 days.
How were Aurobindo Pharma Ltd’s earnings last quarter?
Aurobindo Pharma Ltd released its earnings results on Aug 05, 2026. The company reported ₹17.86 earnings per share for the quarter, beating the consensus estimate of ₹17.262 by ₹0.598.
Is Aurobindo Pharma Ltd overvalued?
According to Wall Street analysts Aurobindo Pharma Ltd’s price is currently Overvalued.
Does Aurobindo Pharma Ltd pay dividends?
Aurobindo Pharma Ltd pays a Notavailable dividend of ₹4 which represents an annual dividend yield of 0.24%. See more information on Aurobindo Pharma Ltd dividends here
What is Aurobindo Pharma Ltd’s EPS estimate?
Aurobindo Pharma Ltd’s EPS estimate is 19.11.
How many shares outstanding does Aurobindo Pharma Ltd have?
Aurobindo Pharma Ltd has 575,377,870 shares outstanding.
What happened to Aurobindo Pharma Ltd’s price movement after its last earnings report?
Aurobindo Pharma Ltd reported an EPS of ₹17.86 in its last earnings report, beating expectations of ₹17.262. Following the earnings report the stock price went up 1.869%.
Which hedge fund is a major shareholder of Aurobindo Pharma Ltd?
Currently, no hedge funds are holding shares in IN:AUROPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aurobindo Pharma Ltd
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Technical Analysis
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Sun Pharmaceutical Industries Limited
―
Torrent Pharmaceuticals Ltd
―
Zydus Lifesciences Limited
―